3 completed, 3 terminated, 1 recruiting. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Terminated 3, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Dexamethasone sodium phosphate: new trials by email Literature Review of Dexamethasone sodium phosphate trials Research Report on Dexamethasone sodium phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| Sterile Amniotic Fluid Filtrate Epidural Injection. Amniotic Fluid Allograft, Dexamethasone sodium phosphate - Lumbar Spinal Stenosis | Phase 1 / Phase 2 | Completed | University of Utah | 58 | 2021-06-16 | 2026-09-25 |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib - Plasmacytoma, Recurrent Multiple Myeloma | Phase 1 | Terminated | National Cancer Institute (NCI) | 35 | 2018-06-14 | 2026-02-10 |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Decitabine, Vorinostat, Vincristine - Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | 23 | 2011-12-01 | 2020-10-27 |
| Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) Erwinase, Vincristine, Dexamethasone - Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase | Phase 1 | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | 1 | 2009-04-13 | 2019-02-19 |
| MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Pomalidomide, Dexamethasone, Aspirin - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Celgene Corporation | 259 | 2008-06-01 | 2016-04-27 |
| Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia ascorbic acid, arsenic trioxide, bortezomib - Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 5 | 2005-05-01 | 2013-04-29 |
Multiple Myeloma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Leukemia (2) · Hypersensitivity (1) · Leukemia, Biphenotypic, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms, Plasma Cell (1) · Plasmacytoma (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Spinal Stenosis (1)
Therapeutic Advances in Childhood Leukemia Consortium (2) · Andrew E. Place, MD (1) · Barbara Ann Karmanos Cancer Institute (1) · Celgene Corporation (1) · National Cancer Institute (NCI) (1) · University of Utah (1)
United States (7) · Australia (1) · Canada (1)
Andrew E Place, MD, PhD (1) · Hans C Lee (1) · Heather Grossman, MD (1) · Jeffrey A. Zonder, MD (1) · Lars A Sternas, MD (1) · Michael Burke, MD (1) · Paul Gaynon, MD (1) · Zachary L McCormick, MD (1)
PMID 23233571, PMID 23243282, PMID 24421329, PMID 27267105, PMID 31969338, PMID 41915069
P30CA022453 (1), UM1CA186688 (1)